Table 3.
Distribution of antibiotic susceptibility patterns of C. difficile isolates based on toxin production.
| Antibiotics | Toxigenic strains (n = 316) | Nontoxigenic strains (n = 222) | |||||||
| A+/B+ (n = 147) | A-/B+ (n = 169) | A-/B- | |||||||
| S | I | R | S | I | R | S | I | R | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Chloramphenicol | 79 (53.74) | 35 (23.8) | 33 (22.44) | 60 (35.5) | 74 (43.78) | 35 (20.71) | 121 (54.5) | 62 (27.92) | 29 (13.06) |
| Penicillin G | 0 (0.00) | 0 (0.00) | 147 (100) | 0 (0.00) | 2 (1.18) | 167 (98.82) | 0 (0.00) | 5 (2.25) | 217 (97.75) |
| Fidaxomicin | 147 (100) | 0 (0.00) | 0 (0.00) | 169 (100) | 0 (0.00) | 0 (0.00) | 222 (100) | 0 (0.00) | 0 (0.00) |
| Vancomycin | 147 (100) | 0 (0.00) | 0 (0.00) | 169 (100) | 0 (0.00) | 0 (0.00) | 222 (100) | 0 (0.00) | 0 (0.00) |
| Metronidazole | 127 (86.39) | 8 (5.44) | 12 (8.16) | 143 (84.61) | 6 (3.55) | 20 (11.83) | 214 (96.39) | 8 (3.6) | 0 (0.00) |
| Rifampin | 127 (86.39) | 11 (7.48) | 9 (6.12) | 151 (89.34) | 7 (4.14) | 11 (6.5) | 215 (96.84) | 7 (3.15) | 0 (0.00) |
| Clindamycin | 20 (13.6) | 21 (14.28) | 106 (72.1) | 28 (16.56) | 32 (18.93) | 109 (64.49) | 41 (18.46) | 25 (11.26) | 156 (70.27) |
| Tetracycline | 70 (47.61) | 13 (8.84) | 64 (43.53) | 66 (39.05) | 34 (20.11) | 69 (40.82) | 85 (38.28) | 30 (13.51) | 107 (63.31) |
| Fusidic acid | 52 (35.37) | 23 (15.64) | 72 (48.97) | 86 (50.88) | 16 (9.46) | 68 (40.23) | 157 (70.72) | 22 (9.9) | 43 (19.36) |
| Linezolid | 142 (96.59) | 2 (1.36) | 3 (2.04) | 168 (99.4) | 1 (0.6) | 0 (0.00) | 219 (98.64) | 1 (0.45) | 2 (0.9) |
| Erythromycin | 35 (23.8) | 0 (0.00) | 112 (76.2) | 54 (31.95) | 0 (0.00) | 115 (68.05) | 46 (20.72) | 0 (0.00) | 176 (79.28) |
| Ciprofloxacin | 18 (12.24) | 4 (2.72) | 125 (85.03) | 22 (13.01) | 6 (3.55) | 141 (83.43) | 29 (13.06) | 0 (0.00) | 193 (86.94) |
| Piperacillin/tazobactam | 130 (88.43) | 11 (7.48) | 6 (4.08) | 154 (91.12) | 6 (3.55) | 9 (5.32) | 207 (93.24) | 7 (3.15) | 8 (3.6) |
| Amoxicillin/clavulanate | 147 (100) | 0 (0.00) | 0 (0.00) | 169 (100) | 0 (0.00) | 0 (0.00) | 222 (100) | 0 (0.00) | 0 (0.00) |
| Trimethoprim/sulphamethoxazole | 14 (9.52) | 0 (0.00) | 133 (90.47) | 7 (4.14) | 0 (0.00) | 162 (95.85) | 1 (0.45) | 0 (0.00) | 221 (99.55) |
| Moxifloxacin | 94 (63.94) | 10 (6.8) | 43 (29.25) | 115 (68.04) | 17 (10.05) | 37 (21.89) | 164 (73.87) | 6 (2.7) | 52 (23.42) |
| Gatifloxacin | 93 (63.26) | 2 (1.36) | 52 (35.37) | 119 (70.41) | 5 (2.95) | 45 (26.62) | 178 (80.18) | 4 (1.8) | 40 (18.01) |
| Levofloxacin | 29 (19.72) | 16 (10.88) | 102 (69.38) | 31 (18.34) | 7 (4.14) | 131 (77.51) | 39 (17.56) | 11 (4.95) | 178 (80.18) |
| Bacitracin | 7 (4.76) | 0 (0.00) | 140 (92.23) | 21 (12.42) | 0 (0.00) | 148 (87.57) | 13 (5.85) | 0 (0.00) | 209 (94.14) |
| Meropenem | 147 (100) | 0 (0.00) | 0 (0.00) | 169 (100) | 0 (0.00) | 0 (0.00) | 222 (100) | 0 (0.00) | 0 (0.00) |
| MDR | 118 (80.27) | 121 (71.6) | 134 (60.36) | ||||||
| 239 (75.93) | |||||||||
S: susceptible, I: intermediate, R: resistant.